An alternative colorimetric RT-LAMP assay for the rapid detection of SARS-CoV-2: development and validation in Thailand
The Journal of Infection in Developing Countries · 2024
DOI: 10.3855/jidc.19442 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Wiphat Klayut und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand. Hauptthemen laut MEDLINE: SARS-CoV-2, Nucleic Acid Amplification Techniques, Colorimetry, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Thailand.
Abstract (Originalsprache)
Introduction
COVID-19, an emerging infectious disease caused by SARS-CoV-2, continues to be a global public health threat. The development of a colorimetric reverse transcription loop-mediated isothermal amplification (RT-LAMP) can extend the availability of simple, reliable molecular tests for the rapid detection of COVID-19. Methodology: The RT-LAMP assay was developed using a new primer set targeting a portion of SARS-CoV-2 orf8. The method was validated at 63 ºC for 60 minutes with naked-eye visualization of the color change. The clinical performance was compared to a real-time reverse transcription-polymerase chain reaction (rtRT-PCR) using 273 RNA samples extracted from nasopharyngeal swab specimens.
Results
The developed RT-LAMP was specific to SARS-CoV-2 with a limit of detection at 15 RNA copies per reaction. The assay demonstrated diagnostic accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of 90.48% (95% CI: 86.36–93.68%), 87.00% (95% CI: 81.53–91.33%), 100% (95% CI: 95.07–100%), 100% (95% CI: not available), and 73.74% (95% CI: 66.22–80.07%), respectively, compared to the rtRT-PCR. The greatest sensitivity of 98.03% (95% CI: 94.34–99.59%) was demonstrated in samples with the cycle threshold (Ct) values < 30 cycles.
Conclusions
The RT-LAMP method in this study showed good performance. The assay can increase the scope of laboratory testing for rapidly detecting SARS-CoV-2 in Thailand. Due to a decrease in COVID-19 cases, its application is beneficial when commercial alternatives are unavailable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.
- Mae Sot Hospital, Ministry of Public Health, Tak, Thailand.
- Regional Medical Sciences Center 5 Samut Songkhram, Department of Medical Sciences, Ministry of Public Health, Samut Songkhram, Thailand.
- Medical Sciences Technical Office, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.
Förderung
- National Research Council of Thailand
Zitieren
APA
Klayut, W., Wongchai, T., Chuenchom, N., Bhakdeenuan, P., Bunchoo, S., Srisungngam, S., Suphankong, S., Phetsuksiri, B., Uppapong, B., & Rudeeaneksin, J. (2024). An alternative colorimetric RT-LAMP assay for the rapid detection of SARS-CoV-2: development and validation in Thailand. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.19442
Vancouver
Klayut W, Wongchai T, Chuenchom N, Bhakdeenuan P, Bunchoo S, Srisungngam S, et al. An alternative colorimetric RT-LAMP assay for the rapid detection of SARS-CoV-2: development and validation in Thailand. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.19442
BibTeX
@article{Klayut2024,
author = {Klayut, Wiphat and Wongchai, Thanee and Chuenchom, Nattagarn and Bhakdeenuan, Payu and Bunchoo, Supranee and Srisungngam, Sopa and Suphankong, Sirilada and Phetsuksiri, Benjawan and Uppapong, Ballang and Rudeeaneksin, Janisara},
title = {An alternative colorimetric RT-LAMP assay for the rapid detection of SARS-CoV-2: development and validation in Thailand},
journal = {The Journal of Infection in Developing Countries},
year = {2024},
doi = {10.3855/jidc.19442}
}
EUVIMED